Summary
Antiglutamatergic acting substances are considered to be useful tools for the treatment of hypokinesia in animal models for Parkinson's disease (PD). Moreover, most known antiglutamatergic compounds act postsynaptically and are either toxic or weak with regard to their clinical potency. The antiepileptic drug “Lamotrigine (LTG)” inhibits presynaptic glutamate release and may therefore provide a novel approach for PD therapy. Encouraging results from a pilot project led us to establish a placebo controlled trial including 20 patients with PD. The substance was generally well tolerated. There was a significant difference in the investigator's overall assessment of efficacy (6/10 vs. 2/10 improvement; p<0.05) and a tendency for LTG to exhibit a beneficial effect in some registration parameters, but no significant differences in motor response were found between the two groups. We failed to confirm that LTG mediates a strong antiparkinsonian effect in this small study, but to clearly demonstrate slight or moderate beneficial effects larger groups are required.
This is a preview of subscription content, log in via an institution to check access.
References
Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12(10): 366–375
Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13(7): 266–271
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381
Betts T, Goodwin G, Withers RM, Yuen AWC (1991) Human safety of lamotrigine. Epilepsia 32 [Suppl 2]: S17-S21
Binnie CD, Van Emde Boas W, Kasteleijn-Nolste-Trenite DGA De Korte RA, Merjer JWA, Meinardi H, Miller AA, Overweg J, Peck AW, Van Wierigen A, Yuen WC (1986) Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27: 248–254
Carlsson A (1993) On the neuronal circuitries and neurotransmitters involved in the control of locomotor activity. J Neural Transm [Suppl] 40: 1–12
Carlsson M, Carlsson A (1989a) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226
Carlsson M, Carlsson A (1989b) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65–71
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13(7): 272–276
Clineschmidt BV, Martin GE, Buntiing PR, Papp NL (1982) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydo-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135–145
Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42: 535–541
DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13(7): 281–285
Greenamyre JT (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm [Gen Sect] 91: 255–269
Jones-Humble SA, Morgan PF, Cooper BR (1994) The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci 54(4): 245–252
Kitai ST, Kita H (1987) Anatomy and physiology of the subthalamic nucleus: a driving force of the basal ganglia. In: Carpenter MB, Jayaraman (eds) The basal ganglia, vol II. Plenum Press, New York, pp 357–373
Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12(8): 285–286
Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Ann Neurol 28: 539–546
Klockgether T, Turski L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30: 717–723
Kornhuber J, Borman J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801 binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol-Mol Pharmacol Sect 206: 297–300
Leach MJ, Baxter MG, Critchley MAE (1991) Neurochemical and behavioral aspects of lamotrigine. Epilepsia 32 [Suppl 2]: S4-S8
Löschmann P-A, Lange KW, Kunow M, Rettig K-J, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBOX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J Neural Transm [P-D Sect] 3: 203–213
McGeer EG, Zhu SG (1990) Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 112: 348–351
Peck AW (1991) Clinical pharmacology of lamotrigine. Epilepsia 32 [Suppl 2] S9-S12
Posner J, Holdich T, Crome P (1991) Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1: 121–128
Riederer P, Kornhuber J, Gerlach M, Danielczyk W, Youdim MBH (1991) Glutamatergic-dopaminergic imbalance in Parkinson's disease and paranoid hallucinatory psychosis. In: Rinne UK, Nagatsu T, Horowski R (eds) International workshop Berlin, Parkinson's disease. Medicom Europe B V, pp 10–23
Rouzaire-Dubois B, Scarnati E (1987a) Increase in glutamate sensitivity of subthalamic nucleus neurons following bilateral decortication: a microiontophoretic study in the rat. Brain Res 403: 366–370
Rouzaire-Dubois B, Scarmati E (1987b) Pharmacological study of the cortical-induced excitation of subthalamic nucleus neurons in the rat: evidence for amino acids as putative neurotransmitters. Neuroscience 21(2) 429–440
Schwab RS, England RC, Poskanzer DC (1969) Amantadine and the treatment of Parkinson's disease. JAMA 208: 1168–1170
Turski L (1991) Excitatory amino acid antagonists and Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R (eds) How to proceed today in treatment. International workshop Berlin Parkinson's Disease. Medicom. Europe B V, pp 97–112
Zipp F, Baas H, Fischer P-A (1993) Lamotrigine-antiparkinsonian activity by blockade of glutamate release? J Neural Transm [P-D Sect] 5: 67–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zipp, F., Bürklin, F., Stecker, K. et al. Lamotrigine in Parkinson's disease — a double blind study. J Neural Transm Gen Sect 10, 199–206 (1995). https://doi.org/10.1007/BF02251231
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02251231